相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
40.0%
招募中
2
20.0%
Unknown
4
40.0%
暂无批准数据
- The NIH's RECOVER-TLC initiative will begin enrolling participants in new Long COVID clinical trials this summer, marking nearly two years since the program launched with promises of urgency for treating this chronic condition. - Three new trials will test low-dose naltrexone in children and young adults, semaglutide (Ozempic/Wegovy) for inflammation, and stellate ganglion block procedures, while a baricitinib study is already enrolling participants. - Patient advocates express disappointment with the timeline delays, noting that despite $1.8 billion in total RECOVER funding, the program has been slow to deliver treatment trials for the tens of millions of Americans affected by Long COVID. - The initiative has received nearly 600 treatment submissions from the Long COVID community and researchers, with protocol working groups currently reviewing trial designs and potential sites.
- The FDA has qualified total hip bone mineral density (BMD) as the first validated surrogate endpoint for osteoporosis clinical trials, potentially reducing trial duration from 2-5 years. - The qualification is based on analysis of data from over 160,000 participants across 52 clinical trials, demonstrating strong association between hip BMD increases and fracture risk reduction. - This regulatory milestone addresses the urgent need for new osteoporosis treatments, as fractures are expected to rise to 3.2 million annually by 2040 with healthcare costs reaching $95 billion per year. - The surrogate endpoint applies specifically to phase 3 trials for post-menopausal women with osteoporosis at risk for fracture, offering an alternative to traditional fracture endpoints.
- The FDA issued draft guidance on December 2 outlining specific product types where six-month non-human primate toxicity testing can be eliminated or reduced, marking significant regulatory progress for New Approach Methodologies (NAMs). - A multi-stakeholder Validation and Qualification Network with dozens of partners including FDA, European Commission, and major pharmaceutical companies like Sanofi and GSK held meetings in July to advance NAMs development. - Industry experts emphasize that NAMs are not ready for complete animal model replacement, as the tools, validation criteria, and regulatory frameworks are still being developed and refined. - The shift toward NAMs requires coordinated collaboration across stakeholders, early regulatory engagement, and investment in high-quality biological materials and AI-driven predictive models to achieve widespread adoption.
- A recent study published in Radiology identifies variability in ultrasound elastography measurements of liver tissue, crucial for interpreting disease progression in clinical trials. - The study, part of the FNIH's NIMBLE project, evaluated SWE and VCTE ultrasound technologies in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). - Researchers found that differences of less than 30.7% in SWE and 35.6% in VCTE measurements may reflect technical variability rather than actual changes in liver stiffness. - These findings will help clinicians avoid unnecessary changes in patient management and guide future studies validating ultrasound technology for clinical trials.
- A new FNIH Biomarkers Consortium study found that some commercial blood tests are accurate enough for clinical use and could replace spinal taps and brain scans in many patients with cognitive impairment. - The study confirmed that certain blood tests have accuracy similar to established cerebrospinal fluid tests in detecting amyloid plaques, with p-tau217 protein levels being the most accurate biomarker. - Six commercial test developers were evaluated using blood samples from the Alzheimer's Disease Neuroimaging Initiative, with results showing some tests are highly accurate while others perform poorly. - The validated blood tests could accelerate drug development by helping researchers select optimal participants for clinical trials and enable earlier detection of Alzheimer's brain changes.
